What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?

Expert Opin Pharmacother. 2023 May-Aug;24(10):1101-1103. doi: 10.1080/14656566.2023.2211765. Epub 2023 May 8.

Authors

Piotr Rutkowski¹, Paweł Rogala¹

Affiliation

¹ Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

PMID: 37144819
DOI: 10.1080/14656566.2023.2211765

No abstract available

Keywords: BRAF; MEK; Melanoma; binimetinib; cobimetinib; dabrafenib; encorafenib; trametinib; vemurafenib.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology
Humans
Melanoma* / drug therapy
Mitogen-Activated Protein Kinase Kinases / therapeutic use
Mutation
Oximes / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Pyridones / therapeutic use
Skin Neoplasms* / drug therapy

Substances

BRAF protein, human
Mitogen-Activated Protein Kinase Kinases
Oximes
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Pyridones